Literature DB >> 33493353

Delineating phenotypes of Kawasaki disease and SARS-CoV-2-related inflammatory multisystem syndrome: A French study and literature review.

Bilade Cherqaoui1,2,3, Isabelle Koné-Paut1,2,4, Hélène Yager1, Fleur Le Bourgeois5, Maryam Piram2,4,6.   

Abstract

OBJECTIVE: To better define the clinical distinctions between the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related paediatric inflammatory multi-system syndrome (PIMS) and Kawasaki disease (kDa).
METHODS: We compared three groups of patients: group 1, cases from our national historic kDa database (kDa-HIS); group 2, patients with kDa admitted to an intensive care unit (kDa-ICU) from both our original cohort and the literature; and group 3, patients with PIMS from the literature.
RESULTS: kDa-HIS included 425 patients (male to female ratio 1.3, mean age 2.8 ± 2.4 years), kDa-ICU 176 (male to female ratio 1.3, mean age 3.5 ± 3.1 years), and PIMS 404 (male to female ratio 1.4, mean age 8.8 ± 3.7 years). As compared with kDa-HIS patients, kDa-ICU and PIMS patients had a higher proportion of cardiac failure and digestive and neurological signs. They also had lower frequency of typical mucocutaneous signs, lower platelet count, higher C-reactive protein level, and lower sodium level. As compared with kDa-HIS and kDa-ICU patients, PIMS patients were older and more frequently had myocarditis. They had fewer coronary abnormalities and lower sodium level. Unresponsiveness to intravenous immunoglobulins was more frequent in kDa-ICU than kDa-HIS and PIMS patients.
CONCLUSION: On clinical grounds, regular kDa, kDa-ICU and PIMS might belong to a common spectrum of non-specific pathogen-triggered hyperinflammatory states. The causes of increasing inflammation severity within the three entities and the different effects on the heart remain to be determined.
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; Intensive Care Unit; Intravenous Immunoglobulins; Kawasaki disease; PIMS/MIS-C; SARS-CoV-2–related inflammatory multisystem syndrome; Shock syndrome; Systemic vasculitis

Year:  2021        PMID: 33493353     DOI: 10.1093/rheumatology/keab026

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  3 in total

1.  Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative study.

Authors:  Gülçin Otar Yener; Ayşenur Paç Kısaarslan; Kadir Ulu; Erdal Atalay; Fatih Haşlak; Semanur Özdel; Burcu Bozkaya Yücel; Deniz Gezgin Yıldırım; Figen Çakmak; Kübra Öztürk; Mustafa Çakan; Zeynep Balık; Canan Hasbal Akkuş; Mehmet Yıldız; Tuğba Erat; Benhur Şirvan Çetin; Münevver Yılmaz; Esra Bağlan; Sibel Laçinel Gürlevik; Vildan Atasayan; Şerife Gül Karadağ; Amra Adrovic; Şengül Çağlayan; Ayşe Tanatar; Fatma Gül Demirkan; Taner Coşkuner; Özlem Akgün; Müşerref Kasap Cüceoğlu; Gülşah Kavrul Kayaalp; Sezgin Şahin; Özge Başaran; Ferhat Demir; Kenan Barut; Murat Çiftel; Dolunay Gürses; Ali Baykan; Yasemin Özsürekçi; Tevfik Karagöz; Hafize Emine Sönmez; Yelda Bilginer; Nuray Aktay Ayaz; Özlem Aydoğ; Selçuk Yüksel; Betül Sözeri; Özgür Kasapçopur; Seza Özen
Journal:  Rheumatol Int       Date:  2021-09-07       Impact factor: 3.580

2.  Comparable bidirectional neutrophil immune dysregulation between Kawasaki disease and severe COVID-19.

Authors:  Kuang-Den Chen; Ying-Hsien Huang; Wei-Sheng Wu; Ling-Sai Chang; Chiao-Lun Chu; Ho-Chang Kuo
Journal:  Front Immunol       Date:  2022-09-08       Impact factor: 8.786

3.  An Immunological Axis Involving Interleukin 1β and Leucine-Rich-α2-Glycoprotein Reflects Therapeutic Response of Children with Kawasaki Disease: Implications from the KAWAKINRA Trial.

Authors:  Christoph Kessel; Isabelle Koné-Paut; Stéphanie Tellier; Alexandre Belot; Katja Masjosthusmann; Helmut Wittkowski; Sabrina Fuehner; Linda Rossi-Semerano; Perrine Dusser; Isabelle Marie; Nadja Boukhedouni; Helène Agostini; Céline Piedvache; Dirk Foell
Journal:  J Clin Immunol       Date:  2022-06-14       Impact factor: 8.542

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.